


## Cudraflavone B

Cat. No.:	HY-N10009
CAS No.:	19275-49-1
Molecular Formula:	C <sub>25</sub> H <sub>24</sub> O <sub>6</sub>
Molecular Weight:	420.45
Target:	NF-κB; TNF Receptor; COX; ERK; p38 MAPK; Sirtuin
Pathway:	NF-κB; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Stem Cell/Wnt; Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Cudraflavone B is a prenylated flavonoid with anti-inflammatory and anti-tumor properties. Cudraflavone B is also a dual inhibitor of COX-1 and COX-2. Cudraflavone B blocks the translocation of nuclear factor κB (NF-κB) from the cytoplasm to the nucleus in macrophages. Thus, Cudraflavone B inhibits tumor necrosis factor α (TNFα) gene expression and secretion. Cudraflavone B also triggers the mitochondrial apoptotic pathway, activates NF-κB, the MAPK p38, and ERK, and induced the expression of SIRT1. Thus Cudraflavone B inhibits the growth of human oral squamous cell carcinoma cells <sup>[1][2]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	NF-κB	COX-2	COX-1	TNFRSF1A
	p38 MAP kinase	ERK	SIRT1	

### REFERENCES

- [1]. Hošek J, et al. Natural compound cudraflavone B shows promising anti-inflammatory properties in vitro. *J Nat Prod.* 2011 Apr 25;74(4):614-9.
- [2]. Lee HJ, et al. Growth inhibition and apoptosis-inducing effects of cudraflavone B in human oral cancer cells via MAPK, NF-κB, and SIRT1 signaling pathway. *Planta Med.* 2013 Sep;79(14):1298-306.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA